Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171987 | 1.00 | KEAP1 (0.35) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL28106406 | 0.85 | — | — | |
| SCHEMBL15347632 | 0.83 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL15228550 | 0.80 | GABRR1 (0.41) | — | |
| SCHEMBL14844316 | 0.80 | GABRR1 (0.41) | — | |
| SCHEMBL4641581 | 0.79 | — | — | |
| SCHEMBL4400744 | 0.79 | ALDH1A1 (0.35) | — | |
| SCHEMBL52 | 0.78 | CA2 (0.35) | — | |
| SCHEMBL27623481 | 0.78 | CA2 (0.35) | — | |
| SCHEMBL3312301 | 0.77 | GABRP (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132821-A1 | Novel heteroaryl derivatives and their use as medicaments | ZENTARIS GMBH (DE) | 2002-09-19 | — | — | US | claimed |
| US-20180071284-A1 | PREVENTING OR TREATING VIRAL INFECTION BY INHIBITION OF THE HISTONE METHYLTRANSFERASE EZH1 OR EZH2 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-03-15 | — | — | US | disclosed |
| US-6706722-B2 | IN PARTICULAR FOR TREATING TUMORS. | ZENTARIS AG (DE) | 2004-03-16 | — | — | US | disclosed |
| US-20020132821-A1 | Novel heteroaryl derivatives and their use as medicaments | ZENTARIS GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071284-A1 | PREVENTING OR TREATING VIRAL INFECTION BY INHIBITION OF THE HISTONE METHYLTRANSFERASE EZH1 OR EZH2 | EZH2, EZH1, EHMT1 | KEAP1 613/4885NFE2L2 1491/4885HCAR2 3465/4885 |
| US-20020132821-A1 | Novel heteroaryl derivatives and their use as medicaments | ABCB1, ABCB11, FANCD2 | KEAP1 2458/4885NFE2L2 155/4885HCAR2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.